NasdaqGM - Nasdaq Real Time Price USD
Intellia Therapeutics, Inc. (NTLA)
15.55 +0.30 (+1.97%)
As of 10:24:05 AM EDT. Market Open.
Trade NTLA on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for NTLA
- Previous Close
15.25 - Open
15.33 - Bid 11.42 x 200
- Ask 19.58 x 200
- Day's Range
15.30 - 16.04 - 52 Week Range
7.95 - 28.25 - Volume
730,782 - Avg. Volume
6,431,454 - Market Cap (intraday)
2.173B - Beta (5Y Monthly) 1.82
- PE Ratio (TTM)
-- - EPS (TTM)
-3.52 - Earnings Date (est.) Aug 6, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.63
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
NTLA
72.97%
S&P 500 (^GSPC)
7.95%
1-Year Return
NTLA
62.49%
S&P 500 (^GSPC)
21.30%
3-Year Return
NTLA
62.05%
S&P 500 (^GSPC)
69.95%
5-Year Return
NTLA
82.09%
S&P 500 (^GSPC)
73.21%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
2.13B
Enterprise Value
1.84B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
27.79
Price/Book (mrq)
3.43
Enterprise Value/Revenue
27.77
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.14%
Return on Equity (ttm)
-56.34%
Revenue (ttm)
66.09M
Net Income Avi to Common (ttm)
-394.6M
Diluted EPS (ttm)
-3.52
Balance Sheet and Cash Flow
Total Cash (mrq)
375.99M
Total Debt/Equity (mrq)
12.96%
Levered Free Cash Flow (ttm)
-235.23M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreIntellia Earnings: Pipeline Makes Progress as Lonvo-Z Succeeds in Phase 3 Trial; Shares Undervalued
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
RatingPrice TargetIntellia Earnings: Pipeline Makes Progress as Lonvo-Z Succeeds in Phase 3 Trial; Shares Undervalued
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
RatingPrice TargetIntellia Earnings: Pipeline Makes Progress as Lonvo-Z Succeeds in Phase 3 Trial; Shares Undervalued
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
RatingPrice TargetIntellia Earnings: Pipeline Makes Progress as Lonvo-Z Succeeds in Phase 3 Trial; Shares Undervalued
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
RatingPrice Target